205 related articles for article (PubMed ID: 38069567)
1. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
2. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study.
Kennedy OJ; Ali N; Lee R; Monaghan P; Adam S; Cooksley T; Lorigan P
Eur J Cancer; 2024 May; 202():113949. PubMed ID: 38432099
[TBL] [Abstract][Full Text] [Related]
5. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
6. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis.
Mosaferi T; Tsai K; Sovich S; Wilhalme H; Kathuria-Prakash N; Praw SS; Drakaki A; Angell TE; Lechner MG
Thyroid; 2022 May; 32(5):496-504. PubMed ID: 35199588
[No Abstract] [Full Text] [Related]
7. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
8. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
9. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
10. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T; Iwama S; Yamagami A; Izuchi T; Suzuki K; Otake K; Yasuda Y; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Hase T; Nishio N; Mori S; Shimokata T; Sano T; Niimi K; Yoshikawa N; Akamatsu S; Ando Y; Akiyama M; Sone M; Ishii M; Arima H
Cancer Immunol Immunother; 2024 Jun; 73(8):146. PubMed ID: 38833157
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience.
Patrizio A; Fallahi P; Antonelli A; Ferrari SM
Curr Pharm Des; 2023; 29(4):295-299. PubMed ID: 35593347
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor.
Sawada T; Narukawa M
Cancer Control; 2024; 31():10732748241244586. PubMed ID: 38581169
[TBL] [Abstract][Full Text] [Related]
14. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study.
Lee HJ; Manavalan A; Stefan-Lifshitz M; Schechter C; Maity A; Tomer Y
Front Endocrinol (Lausanne); 2023; 14():1169173. PubMed ID: 37168978
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and Management of Immune Checkpoint Inhibitor-Induced Hypothyroidism: A Retrospective Analysis.
Phillips AL; Reeves DJ
Ann Pharmacother; 2022 Oct; 56(10):1100-1105. PubMed ID: 35168406
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
18. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
[TBL] [Abstract][Full Text] [Related]
19. Thyroid disorders associated with immune control point inhibitors.
Fidilio E; Navarro-González E; Romero-Lluch AR; Iglesias P; Diez Gómez JJ; Anda Apiñániz E; Santos Mazo E; Zafón C
Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):408-415. PubMed ID: 34742474
[TBL] [Abstract][Full Text] [Related]
20. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
